ACIU (AC Immune) Piotroski F-Score: 2 (As of Jun. 27, 2026) — 33% Below Median


ACIU AC Immune SA ACIU
26 GF Score
Price $2.56
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Piotroski F-Score?

AC Immune ACIU +4.70% 26 Piotroski F-Score is 2 as of Jun. 27, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates ACIU with a GF Score™ of 26/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,342 Biotechnology companies, AC Immune ranks worse than 73.1% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AC Immune has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for AC Immune's Piotroski F-Score or its related term are showing as below:

ACIU' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 6
Current: 2

During the past 12 years, the highest Piotroski F-Score of AC Immune was 6. The lowest was 1. And the median was 3.

AC Immune  (NAS:ACIU) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


AC Immune Piotroski F-Score Related Terms


AC Immune Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for AC Immune's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune Piotroski F-Score Chart

AC Immune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.00 1.00 4.00 2.00

AC Immune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 1.00 2.00 2.00

ACIU vs TRDA, MGNX, SABS: Piotroski F-Score Comparison

For the Biotechnology subindustry, AC Immune's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AC Immune Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where AC Immune's Piotroski F-Score falls into.


ACIU
26GF Score
AC Immune SA ACIU
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -26.056 + -19.92 + -18.036 + -18.8 = $-82.81 Mil.
Cash Flow from Operations was -19.181 + -23.037 + -20.715 + 0 = $-62.93 Mil.
Revenue was 1.606 + 1.18 + 0.424 + 1.421 = $4.63 Mil.
Gross Profit was 1.606 + 1.18 + 0.424 + 1.421 = $4.63 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(238.889 + 233.92 + 215.56 + 193.564 + 174.547) / 5 = $211.296 Mil.
Total Assets at the begining of this year (Mar25) was $238.89 Mil.
Long-Term Debt & Capital Lease Obligation was $4.42 Mil.
Total Current Assets was $101.68 Mil.
Total Current Liabilities was $117.17 Mil.
Net Income was -25.464 + 6.496 + -17.718 + -21.536 = $-58.22 Mil.

Revenue was 0.769 + 30.081 + 1.275 + 1.12 = $33.25 Mil.
Gross Profit was 0.769 + 30.081 + 1.275 + 1.12 = $33.25 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(188.252 + 265.759 + 288.3 + 258.987 + 238.889) / 5 = $248.0374 Mil.
Total Assets at the begining of last year (Mar24) was $188.25 Mil.
Long-Term Debt & Capital Lease Obligation was $4.69 Mil.
Total Current Assets was $172.18 Mil.
Total Current Liabilities was $112.32 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AC Immune's current Net Income (TTM) was -82.81. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AC Immune's current Cash Flow from Operations (TTM) was -62.93. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-82.812/238.889
=-0.34665472

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-58.222/188.252
=-0.30927693

AC Immune's return on assets of this year was -0.34665472. AC Immune's return on assets of last year was -0.30927693. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

AC Immune's current Net Income (TTM) was -82.81. AC Immune's current Cash Flow from Operations (TTM) was -62.93. ==> -62.93 > -82.81 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4.419/211.296
=0.02091379

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=4.688/248.0374
=0.01890038

AC Immune's gearing of this year was 0.02091379. AC Immune's gearing of last year was 0.01890038. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=101.68/117.17
=0.86779892

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=172.175/112.32
=1.53289708

AC Immune's current ratio of this year was 0.86779892. AC Immune's current ratio of last year was 1.53289708. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

AC Immune's number of shares in issue this year was 98.673. AC Immune's number of shares in issue last year was 100.153. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4.631/4.631
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=33.245/33.245
=1

AC Immune's gross margin of this year was 1. AC Immune's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=4.631/238.889
=0.01938557

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=33.245/188.252
=0.17659839

AC Immune's asset turnover of this year was 0.01938557. AC Immune's asset turnover of last year was 0.17659839. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AC Immune has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
AC Immune (ACIU) has a Piotroski F-Score of 2 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on AC Immune and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, AC Immune's Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, AC Immune ranks #981 out of 1342 companies in the Biotechnology industry, placing it in the top 73.1%.
Is AC Immune's Piotroski F-Score too high?
AC Immune's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. AC Immune's value of 2 is 33.3% below this industry median. Based on the distribution chart, AC Immune ranks #981 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AC Immune has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Piotroski F-Score compare to TRDA and MGNX?
According to the Biotechnology industry distribution chart, AC Immune ranks #981 out of 1342 companies for Piotroski F-Score. This places AC Immune in the lower half of its industry. The industry median Piotroski F-Score is 3.00. AC Immune's value of 2 is 33.3% below this benchmark. Historically, AC Immune's own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, AC Immune has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AC Immune's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on AC Immune and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AC Immune's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.56 — trading 241.3% above its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. AC Immune's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For AC Immune (ACIU), the current Piotroski F-Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.56 is trading 241.3% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
  • GF Value™: $0.75 vs. price of $2.56 (241.3% above fair value)
  • GF Score™: 26/100 with 6 warning signs
  • Industry Position: 33.3% below the Biotechnology median (#981 of 1342)

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score

Get the complete analysis for ACIU

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price
$0.75
GF Value